In Vitro Synergy of Isavuconazole Combined With Colistin Against Common Candida Species
Interactions of isavuconazole and colistin were evaluated against 57 common Candida strains belonging to the species Candida albicans (n = 10), Candida glabrata (n = 10), Candida kefyr (n = 8), Candida krusei (n = 10), Candida parapsilosis (n = 9), and Candida tropicalis (n = 10) by a broth micro...
Պահպանված է:
Հիմնական հեղինակներ: | , , , , , |
---|---|
Ձևաչափ: | Հոդված |
Լեզու: | անգլերեն |
Հրապարակվել է: |
Philipps-Universität Marburg
2022
|
Խորագրեր: | |
Առցանց հասանելիություն: | PDF ամբողջական տեքստ |
Ցուցիչներ: |
Ավելացրեք ցուցիչ
Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!
|
Ամփոփում: | Interactions of isavuconazole and colistin were evaluated against 57 common Candida
strains belonging to the species Candida albicans (n = 10), Candida glabrata (n = 10),
Candida kefyr (n = 8), Candida krusei (n = 10), Candida parapsilosis (n = 9), and Candida
tropicalis (n = 10) by a broth microdilution checkerboard technique based on the
European Committee on Antimicrobial Susceptibility Testing (EUCAST) reference
methodology for antifungal susceptibility testing. Results were analyzed with the
fractional inhibitory concentration index and by the response surface analysis.
Interpretation by the fractional inhibitory concentration index showed synergy for 50%,
80%, 90%, and 90% of the C. kefyr, C. krusei, C. glabrata, and C. tropicalis strains,
respectively. Combination of isavuconazole with colistin against C. albicans and C.
parapsilosis exhibited only indifference for 100% and 90% of the strains, respectively.
The results were confirmed by response surface analysis for all species except for C.
glabrata, for which an indifferent interaction was found for the majority of strains.
Antagonistic interaction was never seen regardless of the interpretation model was used. |
---|---|
Նյութի նկարագրություն: | Gefördert durch den Open-Access-Publikationsfonds der UB Marburg. |
Ֆիզիկական նկարագրություն: | 8 Seiten |
DOI: | 10.3389/fcimb.2022.892893 |